Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Random

Display 15 Products per page

Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

$599.00

Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.
March 9, 2017
Find out more
U.S. Markets for Stroke Management

$4,750.00

The United States (U.S.) market for stroke management products, which encompasses diagnostic and therapeutic systems, is a market composed of old and new technologies that are often used together in order to prevent and treat stroke. Improvements in stroke diagnostic systems will facilitate the delivery of timely stroke therapies within the optimum treatment window for patients suffering from stroke.
September 22, 2016
Find out more
Bydureon
Read More
Bydureon (exenatide long-acting release; AstraZeneca) is a member of the glucagon-like peptide-1 (GLP-1) agonist class.
November 7, 2017
Find out more
NovoEight
Read More
NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
May 4, 2018
Find out more
Cimzia
Read More
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.
July 31, 2018
Find out more
TS-1
Read More
TS-1 (Otsuka/Nordic Group) is an orally available cytotoxic drug that contains gimeracil, oteracil potassium, and tegafur as active ingredients.
December 11, 2017
Find out more
Farletuzumab
Read More
Drug Overview Farletuzumab is a folate receptor alpha (FRa)-targeted monoclonal antibody being developed by Eisai. It is composed of grafted murine complementarity-determining regions on a human IgG1 kappa backbone. Inhibiting FRa can decrease cellular proliferation through inhibition of both Lyn kinase substrate phosphorylation and the interaction between Lyn tyrosine kinase and membrane signaling complexes; effectively […]
August 17, 2017
Find out more
Cyramza
Read More
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.
September 9, 2019
Find out more
Empliciti
Read More
Empliciti is a MAb that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1.
August 9, 2018
Find out more
Big Pharma Outlook 2026

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.
June 29, 2017
Find out more
Abemaciclib
Read More
Abemaciclib is a small molecule inhibitor of cyclin-dependent kinase (CDK)4 and CDK6 in Phase III development for non-small cell lung cancer and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer by Eli Lilly
November 14, 2016
Find out more
Biosimilars Market Access in the US

$2,995.00

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.
October 23, 2015
Find out more
Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

$2,995.00

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.
October 17, 2016
Find out more
France Regulatory Issues

$2,995.00

The much-criticized delay in the removal of marketing authorization for Servier’s Mediator in France has had profound implications for reform of the country’s regulatory system.
November 2, 2016
Find out more
United Kingdom, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union member state of the U.K.
September 22, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *